{
    "2018-11-06": [
        [
            {
                "time": "",
                "original_text": "我们研究了三年的上市公司数据，发现了跑赢大盘的秘密",
                "features": {
                    "keywords": [
                        "上市公司",
                        "数据",
                        "跑赢大盘",
                        "秘密"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "2018-11",
                "original_text": "医药生物2018年三季报总结暨11月投资策略：一阳来复，否极泰来",
                "features": {
                    "keywords": [
                        "医药生物",
                        "三季报",
                        "投资策略",
                        "一阳来复",
                        "否极泰来"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "(互动)华兰生物：四价流感疫苗销售良好 供不应求",
                "features": {
                    "keywords": [
                        "华兰生物",
                        "四价流感疫苗",
                        "销售良好",
                        "供不应求"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "医药三季报总结:医药大数据,成长依旧,估值近前低,正是战略布局好时机",
                "features": {
                    "keywords": [
                        "医药",
                        "三季报",
                        "大数据",
                        "成长",
                        "估值",
                        "战略布局"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}